BioCentury | Dec 3, 2020

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen Horowitz, Menlo Ventures, Radical Ventures,...
BioCentury | Mar 12, 2020

March 11 Quick Takes: PDL, Kala, InnoCare, LifeSci, BioSight, BillionToOne, SEC

PDL to dissolve by year-end PDL BioPharma Inc. (NASDAQ:PDLI) said it will cease operations and seek to sell the company or monetize its assets. PDL acquires commercial-stage pharmaceutical assets and late clinical stage products. On...
BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Cardiovascular; hemophilia Mouse studies suggest BST1- and CD200-positive vascular endothelial cells could help treat vascular injury and hemophilia. In a mouse model of liver vascular injury, transplantation at the injury site of vascular endothelial...
BioCentury | Jan 5, 2018
Clinical News

BioSight reports Phase I/II data for AML candidate

BioSight Ltd. (Airport City, Israel) reported final data from 14 evaluable patients with newly diagnosed acute myelogenous leukemia (AML) in the Phase I/II BSTPHASE1-01 trial showing that BST-236 (astarabine) led to a median overall survival...
BioCentury | May 28, 2012
Clinical News

BST-CarGel: Phase III data

An international, blinded Phase III trial in 80 patients aged 18-55 with single symptomatic grade III/IV focal lesions on femoral condyles showed that BST-CarGel met the co-primary endpoints of greater lesion filling and superior repair...
BioCentury | Nov 17, 2011
Distillery Therapeutics

Indication: Infectious disease

...BST2-expressing human peripheral blood monocytes, BST2 knockdown lowered CMV entry and infection compared with wild-type BST2...
...knockdown lowered CMV entry and infection compared with wild-type BST2 expression. Planned work includes testing BST2...
BioCentury | Oct 27, 2011
Distillery Therapeutics

Indication: Hepatic disease

...Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Hepatic disease IL-15; bone marrow stromal cell antigen 2 (BST2; CD317...
BioCentury | Apr 5, 2010

2Q Financial Markets Preview: Wanted Dry Powder

Biotech run-ups have historically cooled after 25-30% gains. Thus the question going into the second quarter is whether there's momentum to keep going, or whether the sector will take a breather. The historical numbers are...
BioCentury | Dec 3, 2009
Distillery Techniques

Technology: Assays & screens

...systemic therapy. Isolation of the labeled proteins in combination with mass spectrometry identified bone marrow stromal cell antigen 2 (BST2; CD317...
...more than 10-fold in lymphoma-bearing mice compared with what was seen in normal mice. An anti-BST2...
Items per page:
1 - 10 of 38